Olema Pharmaceuticals, Inc. (OLMA)Healthcare | Biotechnology | San Francisco, United States | NasdaqGS
11.85 USD
-0.06
(-0.504%) ⇩
(July 13, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:11 a.m. EDT
The investment case for Olema is currently fractured between a deteriorating business reality and aggressive index-driven speculation. Fundamentally, the company is in a severe decline; despite a temporary rebound in 2023 and 2024, the stock has lost over 80% of its value over the last four years, and the most recent annual performance was a crushing 63% drop. With negative earnings, negative free cash flow, and a beta of 2.0, the underlying business is highly volatile and unprofitable. The recent inclusion in the Russell Growth index has created a mechanical buying floor, pushing the price up 22% recently, but this appears to be a contrarian trap rather than a genuine turnaround. The market is pricing in a potential collapse, as evidenced by the overwhelming options activity where traders are buying deep out-of-the-money puts to protect against further losses, while call buyers are chasing unrealistic moonshot scenarios. Until the pipeline shows definitive clinical success or revenue turns positive, the risk-reward profile remains skewed heavily toward the downside. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.248774 |
| AutoTheta | 0.248907 |
| AutoARIMA | 0.250699 |
| MSTL_79 | 0.259263 |
| MSTL | 0.279189 |
| MSTL_79_126 | 0.371976 |
| MSTL_126 | 0.442185 |
Forecast horizon: 60 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 27% |
| H-stat | 21.33 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.199 |
| Excess Kurtosis | -1.01 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.823 |
| Market Cap | 1,035,067,584 |
| Forward P/E | -4.77 |
| Beta | 2.01 |
| Website | https://olema.com |
As of July 11, 2026, 3:11 a.m. EDT: Speculators are positioning heavily for downside protection, evidenced by massive open interest in deep out-of-the-money puts (strikes 20 and 32) expiring in December 2026, which dwarfs call activity. Conversely, call volume is concentrated in strikes far above the current price (34-37), suggesting speculative bets on a massive recovery rather than a near-term bounce. Implied volatility is extremely compressed for near-term contracts, indicating a lack of pricing for immediate moves, while the heavy put wall suggests a 'floor' is being built at significantly lower levels.
| Attribute | Value |
|---|---|
| 52 Week Change | 1.5816994 |
| Address1 | 780 Brannan Street |
| All Time High | 60.27 |
| All Time Low | 2.0 |
| Ask | 14.78 |
| Ask Size | 2 |
| Audit Risk | 4 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 1,566,910 |
| Average Daily Volume3 Month | 1,434,449 |
| Average Volume | 1,434,449 |
| Average Volume10Days | 1,566,910 |
| Beta | 2.006 |
| Bid | 8.63 |
| Bid Size | 2 |
| Board Risk | 6 |
| Book Value | 5.502 |
| City | San Francisco |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.85 |
| Current Ratio | 10.881 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 12.02 |
| Day Low | 11.45 |
| Debt To Equity | 0.823 |
| Display Name | Olema Pharmaceuticals |
| Earnings Timestamp | 1,778,589,000 |
| Earnings Timestamp End | 1,786,365,000 |
| Earnings Timestamp Start | 1,786,365,000 |
| Ebitda | -191,330,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.789 |
| Enterprise Value | 533,676,544 |
| Eps Current Year | -2.27389 |
| Eps Forward | -2.4817 |
| Eps Trailing Twelve Months | -2.02 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.271 |
| Fifty Day Average Change | -0.42099953 |
| Fifty Day Average Change Percent | -0.034308493 |
| Fifty Two Week Change Percent | 158.16994 |
| Fifty Two Week High | 36.259 |
| Fifty Two Week High Change | -24.408998 |
| Fifty Two Week High Change Percent | -0.6731846 |
| Fifty Two Week Low | 4.37 |
| Fifty Two Week Low Change | 7.4800005 |
| Fifty Two Week Low Change Percent | 1.7116706 |
| Fifty Two Week Range | 4.37 - 36.259 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,605,796,200,000 |
| Float Shares | 59,722,960 |
| Forward Eps | -2.4817 |
| Forward P E | -4.774953 |
| Free Cashflow | -78,798,872 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 137 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01796 |
| Held Percent Institutions | 1.19443 |
| Implied Shares Outstanding | 87,347,471 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,020-11-19 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California. |
| Long Name | Olema Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 1,035,067,584 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_540573682 |
| Most Recent Quarter | 1,774,915,200 |
| Net Income To Common | -185,151,008 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,035,067,531 |
| Number Of Analyst Opinions | 10 |
| Open | 11.9 |
| Operating Cashflow | -148,724,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 415 651 3316 |
| Pre Market Change | 0.14999962 |
| Pre Market Change Percent | 1.2658195 |
| Pre Market Price | 12.0 |
| Pre Market Time | 1,784,033,851 |
| Previous Close | 11.91 |
| Price Eps Current Year | -5.211334 |
| Price Hint | 2 |
| Price To Book | 2.1537623 |
| Profit Margins | 0.0 |
| Quick Ratio | 10.785 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.33333 |
| Region | US |
| Regular Market Change | -0.0599995 |
| Regular Market Change Percent | -0.503774 |
| Regular Market Day High | 12.02 |
| Regular Market Day Low | 11.45 |
| Regular Market Day Range | 11.45 - 12.02 |
| Regular Market Open | 11.9 |
| Regular Market Previous Close | 11.91 |
| Regular Market Price | 11.85 |
| Regular Market Time | 1,783,972,800 |
| Regular Market Volume | 1,219,278 |
| Return On Assets | -0.25499 |
| Return On Equity | -0.42863 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 87,347,471 |
| Shares Percent Shares Out | 0.1607 |
| Shares Short | 14,033,964 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 11,927,602 |
| Short Name | Olema Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.19520001 |
| Short Ratio | 6.81 |
| Source Interval | 15 |
| State | CA |
| Symbol | OLMA |
| Target High Price | 62.0 |
| Target Low Price | 23.0 |
| Target Mean Price | 40.7 |
| Target Median Price | 40.0 |
| Total Cash | 505,347,008 |
| Total Cash Per Share | 5.785 |
| Total Debt | 3,956,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.02 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 17.35545 |
| Two Hundred Day Average Change | -5.5054493 |
| Two Hundred Day Average Change Percent | -0.31721732 |
| Type Disp | Equity |
| Volume | 1,219,278 |
| Website | https://olema.com |
| Zip | 94,103 |